VistaGen Therapeutics (NASDAQ: VTGN) Featured Research Report

24 A EGIS C APITAL C ORP. Sources 1. https://www.ncbi.nlm.nih.gov/pubmed/27561175 2. VistaGen 3. https://adaa.org/understanding-anxiety/social-anxiety-disorder 4. https://www.webmd.com/anxiety-panic/guide/mental-health-social-anxiety-disorder#1 5. https://www.nimh.nih.gov/health/publications/social-anxiety-disorder-more-than-just-shyness/index.shtml 6. https://adaa.org/resources-professionals/clinical-practice-review-social- anxiety#:~:text=Medications%20in%20these%20classes%20that,release%2C%20and%20venlafaxine%20extended%20release 7. https://www.mayoclinic.org/diseases-conditions/depression/symptoms-causes/syc-20356007 8. American Journal of Psychiatry 2014 171:675-682 (Liebowitz, et al) 9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5573566/ 10. https://www.nimh.nih.gov/health/statistics/major-depression.shtml Mentioned Armour Not rated Echo Not rated Sontra Not rated Durham Not rated Morrison & Foerster Not rated SciClone Not rated Celerity Not rated Cato Not rated Excaliber Not rated Hayden Not rated MZ Group Not rated Artemis Not rated Progenitor Not rated Lineberger Not rated Basel Institute Not rated Calypte Not rated California & Hawaiian Not rated Discovery Not rated AstraZeneca Not rated Shire Not rated Alliance Advisors Not rated Stellar Not rated VistaGen Therapeutics, Inc. October 8, 2020